CAPS
MCID: CTS005
MIFTS: 42

Catastrophic Antiphospholipid Syndrome (CAPS)

Categories: Blood diseases, Bone diseases, Immune diseases, Rare diseases

Aliases & Classifications for Catastrophic Antiphospholipid Syndrome

MalaCards integrated aliases for Catastrophic Antiphospholipid Syndrome:

Name: Catastrophic Antiphospholipid Syndrome 52 58 71
Catastrophic Antiphospholipid Antibody Syndrome 52
Cryopyrin-Associated Periodic Syndromes 71
Thrombotic Storm 52
Catastrophic Aps 58
Caps 58

Classifications:

Orphanet: 58  
Rare systemic and rhumatological diseases
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 D68.6
Orphanet 58 ORPHA464343
UMLS 71 C2316212 C3662487

Summaries for Catastrophic Antiphospholipid Syndrome

NIH Rare Diseases : 52 Catastrophic antiphospholipid syndrome (CAPS) is a rare form of antiphospholipid syndrome (APS). In CAPS multiple blood clots form throughout the body over a short period of time (usually within a week). CAPS is a medical emergency, as clots can cause life-threatening multi-organ failure. The cause of CAPS is unknown. A widely accepted explanation is that it is caused by a combination of gene mutations (making one more susceptible to CAPS) and an environmental trigger, such as an infection, trauma, or surgery.

MalaCards based summary : Catastrophic Antiphospholipid Syndrome, also known as catastrophic antiphospholipid antibody syndrome, is related to thrombotic microangiopathy and heparin-induced thrombocytopenia. An important gene associated with Catastrophic Antiphospholipid Syndrome is APOH (Apolipoprotein H), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Formation of Fibrin Clot (Clotting Cascade). The drugs Propofol and Metformin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are homeostasis/metabolism and mortality/aging

Related Diseases for Catastrophic Antiphospholipid Syndrome

Diseases related to Catastrophic Antiphospholipid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 318)
# Related Disease Score Top Affiliating Genes
1 thrombotic microangiopathy 31.4 CFH ADAMTS13
2 heparin-induced thrombocytopenia 30.9 F3 CD40LG
3 antiphospholipid syndrome 30.6 SERPINE1 MTHFR F5 F3 CFH CD40LG
4 hepatic infarction 30.5 F3 APOH
5 cerebritis 30.4 CD40LG APOH
6 prothrombin deficiency 30.3 F3 APOH
7 hemolytic-uremic syndrome 30.2 F3 CFH CD40LG ADAMTS13
8 splenic infarction 30.2 F3 CD40LG APOH
9 hemolytic anemia 30.1 F3 CFH CD40LG APOH ADAMTS13
10 disseminated intravascular coagulation 30.1 SERPINE1 F5 F3 ADAMTS13
11 acquired hemophilia 30.1 F5 F3
12 mixed connective tissue disease 30.1 CD40LG APOH ADAMTS13
13 eclampsia 30.1 SERPINE1 MTHFR APOH
14 coronary thrombosis 30.0 SERPINE1 F3
15 thrombotic thrombocytopenic purpura 30.0 F3 CFH CD40LG APOH ADAMTS13
16 malignant hypertension 30.0 CFH ADAMTS13
17 anuria 30.0 F3 CD40LG ADAMTS13
18 central retinal artery occlusion 30.0 MTHFR CD40LG
19 ischemic colitis 29.9 SERPINE1 F5 APOH
20 hemolytic uremic syndrome, atypical 1 29.9 F3 CFH ADAMTS13
21 myelitis 29.7 MTHFR CD40LG APOH
22 purpura 29.6 PROC F3 CD40LG APOH ADAMTS13
23 severe pre-eclampsia 29.6 SERPINE1 F5 CFH APOH
24 venous insufficiency 29.3 SERPINE1 MTHFR F5
25 central retinal vein occlusion 29.3 MTHFR F5 F3 APOH
26 intracranial thrombosis 29.2 MTHFR F5 F3 APOH
27 budd-chiari syndrome 29.2 MTHFR F5 F3 APOH
28 placenta disease 29.1 MTHFR F5 F3 APOH
29 kidney disease 29.1 SERPINE1 MTHFR F3 CFH
30 purpura fulminans 29.1 PROC F5 F3 APOH
31 retinal artery occlusion 29.0 SERPINE1 MTHFR F5 APOH
32 homocysteinemia 29.0 SERPINE1 MTHFR F5 APOH
33 systemic lupus erythematosus 29.0 SERPINE1 HLA-DRB4 F3 CFH CD40LG APOH
34 pre-eclampsia 28.8 SERPINE1 MTHFR F5 F3 CD40LG APOH
35 thrombophilia due to thrombin defect 28.6 SERPINE1 PROC MTHFR F5 F3 APOH
36 thrombocytopenia 28.5 SERPINE1 MTHFR F5 F3 CFH CD40LG
37 stroke, ischemic 28.5 SERPINE1 MTHFR F5 F3 APOH ADAMTS13
38 retinal vein occlusion 28.3 SERPINE1 MTHFR F5 F3 CD40LG APOH
39 hellp syndrome 28.3 SERPINE1 MTHFR F5 F3 CFH CD40LG
40 protein c deficiency 28.2 SERPINE1 PROC MTHFR F5 APOH
41 patent foramen ovale 28.2 SERPINE1 MTHFR F5 F3 CD40LG APOH
42 pulmonary embolism 27.9 SERPINE1 PROC MTHFR F5 F3 CD40LG
43 thrombophilia 27.8 SERPINE1 PROC MTHFR F5 F3 CD40LG
44 protein s deficiency 27.7 SERPINE1 PROC MTHFR F5 F3 APOH
45 myocardial infarction 27.5 SERPINE1 MTHFR F5 F3 CFH CD40LG
46 thrombophlebitis 27.3 SERPINE1 PROC MTHFR F5 F3 CD40LG
47 thrombosis 27.2 SERPINE1 PROC MTHFR F5 F3 CD40LG
48 lupus erythematosus 10.5
49 autoimmune disease 10.5
50 respiratory failure 10.4

Graphical network of the top 20 diseases related to Catastrophic Antiphospholipid Syndrome:



Diseases related to Catastrophic Antiphospholipid Syndrome

Symptoms & Phenotypes for Catastrophic Antiphospholipid Syndrome

MGI Mouse Phenotypes related to Catastrophic Antiphospholipid Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.61 ADAMTS13 APOH CD40LG CFH F3 F5
2 mortality/aging MP:0010768 9.32 ADAMTS13 APOH CD40LG CFH CRLS1 F3

Drugs & Therapeutics for Catastrophic Antiphospholipid Syndrome

Drugs for Catastrophic Antiphospholipid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 453)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
2
Metformin Approved Phase 4 657-24-9 14219 4091
3
Trandolapril Approved Phase 4 87679-37-6 5484727
4
Captopril Approved Phase 4 62571-86-2 44093
5 Taurolidine Approved, Investigational Phase 4 19388-87-5
6
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
7
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
8
Didanosine Approved Phase 4 69655-05-6 50599
9
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
10
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
11
Histamine Approved, Investigational Phase 4 51-45-6 774
12
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
13
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
14
Citalopram Approved Phase 4 59729-33-8 2771
15
Sertraline Approved Phase 4 79617-96-2 68617
16
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
17
Topiramate Approved Phase 4 97240-79-4 5284627
18
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
19
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
20
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
21
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
22
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
23
Iodine Approved, Investigational Phase 4 7553-56-2 807
24
Povidone Approved Phase 4 9003-39-8
25
Povidone-iodine Approved Phase 4 25655-41-8
26
Ziprasidone Approved Phase 4 146939-27-7 60854
27
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
28
Levetiracetam Approved Phase 4 102767-28-2 441341
29
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
30
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
31
Simvastatin Approved Phase 4 79902-63-9 54454
32
Memantine Approved, Investigational Phase 4 19982-08-2 4054
33
tannic acid Approved Phase 4 1401-55-4
34
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
35
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
36
Ferrous fumarate Approved Phase 4 141-01-5
37
Promethazine Approved, Investigational Phase 4 60-87-7 4927
38
Suvorexant Approved, Investigational Phase 4 1030377-33-3
39
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
40
Colestipol Approved Phase 4 26658-42-4
41
Prazosin Approved Phase 4 19216-56-9 4893
42
Lopinavir Approved Phase 4 192725-17-0 92727
43
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
44
Propranolol Approved, Investigational Phase 4 525-66-6 4946
45
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
46
Ambrisentan Approved, Investigational Phase 4 177036-94-1 6918493
47
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
48
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
49
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
50
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 457)
# Name Status NCT ID Phase Drugs
1 A Randomized , Controlled, Doulbe Blind Placebo Trial To Evaluate The Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
2 Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1b for Treatment of MS Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
3 Acute Haemodynamic Effects of Treatment With ACE-Inhibitors in Patients With Symptomatic Aortic Stenosis (ACCESS) Unknown status NCT00252317 Phase 4 Captopril and Trandolapril;Captopril Test Dose and Trandolapril
4 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
5 Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD:a Multicentre Randomised Controlled Trial Unknown status NCT02937974 Phase 4 Xuebijing;Placebo
6 Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza. Unknown status NCT00934219 Phase 4 Omega-3-Acid Ethyl Esters
7 Taurolidine Citrate and Unfractionated Heparin Combination Versus Unfractionated Heparin Alone in Prevention of Inflammation in Hemodialysis Catheters. Unknown status NCT03539718 Phase 4 Taurolidine heparin;Heparin Sodium
8 A Double-Blind, Placebo-Controlled, Flexible-Dose Pilot Clinical Trial of Once-Daily Extended-Release Tramadol for the Treatment of PTSD Unknown status NCT01517711 Phase 4 Tramadol;Placebo
9 Treatment of Plantar Fasciitis With Injection af Platelet-rich Plasma Into the Origin of the Plantar Fascia - a Prospective, Randomized and Double Blinded Study. Unknown status NCT01509274 Phase 4
10 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
11 Effect Of Dexmedetomidine Infusion On Sublingual Microcirculation In Patients Undergoing On Pump Coronary Artery Bypass Graft Surgery Unknown status NCT02714725 Phase 4 Dexmedetomidine;Placebo for Dexmedetomidine normal saline infusion;Propofol infusion
12 Efficacy and Safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean Patients With Cold Hypersensitivity in the Hands Completed NCT02645916 Phase 4 Danggui-Sayuk-Ga-Osuyu-Saenggang-tang;Placebo: corn starch
13 Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet : a Randomized, Double-blind, Placebo-controlled Trial Completed NCT01664156 Phase 4 Korean red ginseng;Placebo
14 A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence Completed NCT00785616 Phase 4
15 Cathflo Activase (Alteplase) Pediatric Study (CAPS) Completed NCT00307580 Phase 4 Cathflo Activase (Alteplase)
16 Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens Completed NCT00177333 Phase 4 Doxycycline
17 Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia: an 8-week, Randomized, Double-blind, Placebo-controlled Trial Completed NCT00847600 Phase 4
18 Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD) Completed NCT00203463 Phase 4 topiramate
19 A Placebo-controlled Trial of Adjunctive Quetiapine for Refractory PTSD Completed NCT00292370 Phase 4 Open Label (OL) Paroxetine;Placebo;Quetiapine
20 Randomized Clinical Trial to Study the Topiramate Efficacy for Posttraumatic Disorder Treatment Completed NCT00725920 Phase 4 Topiramate;placebo control group
21 An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder Completed NCT02258828 Phase 4 Memantine;Placebo
22 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4 Paroxetine CR
23 Prazosin Treatment for Combat Trauma PTSD Nightmares and Sleep Disturbance Completed NCT00108420 Phase 4 Prazosin
24 Immediate and Delayed Loading of 4.1 mm and 4.8 mm Implants in the Posterior Mandible & Maxilla: A Controlled Randomized Study of Single or 2-4 Unit Restorations Loaded Immediately After Surgery or Four Weeks After Surgery Completed NCT00782171 Phase 4
25 Locking of Totally Implanted Venous Access Devices and Tunneled Catheters With or Without Heparin: a Randomised Open-labeled Controlled Trial Completed NCT00994136 Phase 4 normal saline
26 Exercise and Phytoestrogens: a Synergistic Effect on Factors Predisposing to CVD in Postmenopausal Women Completed NCT01048606 Phase 4
27 Risperidone Monotherapy in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma: a Double-Blind, Placebo Controlled, Randomized Clinical Trial Completed NCT00208182 Phase 4 Risperidone
28 Skin Antisepsis With Chlorhexidine-Alcohol Versus Povidone Iodine-Alcohol, Combined or Not With Use of a Bundle of New Devices, for Prevention of Intravascular-catheter Colonization and Catheter Failure: An Open Label, Single Center, Randomized Controlled, Two-by-two Factorial Trial Completed NCT03757143 Phase 4 Povidone-Iodine-Alcohol;Chlorhexidine-Alcohol
29 Randomized, Controlled, Double Blind Trial to Evaluate Sedation and Quality of Life in High-risk, Critically Ill Patients Treated With Oral Melatonin Completed NCT00470821 Phase 4 Oral melatonin 3mg BID;Placebo
30 Geodon (Ziprasidone) for Posttraumatic Stress Disorder Completed NCT00208208 Phase 4 Ziprasidone
31 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Posttraumatic Stress Disorder in Civilians Completed NCT00208130 Phase 4 Topiramate
32 Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder Completed NCT01681849 Phase 4 Placebo;Paroxetine
33 A Placebo-Controlled Study of Mirtazapine for PTSD in OIF/OEF Veterans Completed NCT00302107 Phase 4 Mirtazapine;Placebo
34 Combined Mirtazapine and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment of Post-traumatic Stress Disorder (PTSD) Completed NCT01178671 Phase 4 Mirtazapine;Sertraline
35 Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study Completed NCT02287038 Phase 4 Atomoxetine 80 MG
36 Evaluation of Clinical and Safety Outcomes Associated With Conversion From Brand-Name to Generic Tacrolimus Products in High Risk Transplant Recipients Completed NCT02014103 Phase 4 Tacrolimus
37 A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epilepsy. Completed NCT00438451 Phase 4 Levetiracetam;Carbamazepine;Lamotrigine
38 Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
39 A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of Citicoline as an add-on Therapy Will be Conducted in 200 Outpatients With Bipolar I Disorder and Cocaine Dependence. Completed NCT00619723 Phase 4 Citicoline;Placebo
40 Energy Expenditure Assessment of Preterm Infant With Very Low Birth Weight Fed With Human Milk or Preterm Formula Completed NCT00769509 Phase 4
41 Antidepressant Treatment at an Inner City Asthma Clinic Completed NCT01324700 Phase 4 High severity group: Escitalopram;High severity group: Placebo;Low severity group: Escitalopram;Low severity group: Placebo
42 Magnetic Resonance Characterization of Carotid Atherosclerotic Plaque in Vivo: Effect of High Density Lipoprotein Elevation on Plaque Morphology Completed NCT00307307 Phase 4 Niacin/simvastatin compared to simvastatin alone at 2 doses
43 Randomized Double-blind Placebo-controlled Trial of Memantine Hydrochloride for the Treatment of Childhood-onset Epileptic Encephalopathies Recruiting NCT03779672 Phase 4 Memantine Hydrochloride 10 mg
44 Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial Recruiting NCT03830034 Phase 4 Amino Acid chelated iron tab 15 mg;Ferrous Fumarate tab 350 mg( 115 mg elemental iron)
45 Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance inPosttraumatic Stress Recruiting NCT03642028 Phase 4 Suvorexant
46 Treatment Effect of Colesevelam for Bile Acid Diarrhoea - a Randomised Placebo-controlled Trial Recruiting NCT03876717 Phase 4 Colesevelam Hydrochloride;Placebo oral capsule
47 Propranolol Reactivation Mismatch (PRM) Treatment for PTSD: A Pilot Study Not yet recruiting NCT03652922 Phase 4 Reactivation Mismatch
48 Administration of Prazosin to Prevent PTSD After Sexual Assault Not yet recruiting NCT03997864 Phase 4 Prazosin;Placebos
49 PTSD Symptom Reduction by Propranolol Given After Memory Activation Terminated NCT00645450 Phase 4 Propranolol;Placebo
50 The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study (The CAPS-PAH Study) Terminated NCT02253394 Phase 4 Ambrisentan plus Spironolactone;Ambrisentan plus Placebo

Search NIH Clinical Center for Catastrophic Antiphospholipid Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


anakinra

Genetic Tests for Catastrophic Antiphospholipid Syndrome

Anatomical Context for Catastrophic Antiphospholipid Syndrome

MalaCards organs/tissues related to Catastrophic Antiphospholipid Syndrome:

40
Brain, Testes, Heart, Breast, Liver, Lung, Eye

Publications for Catastrophic Antiphospholipid Syndrome

Articles related to Catastrophic Antiphospholipid Syndrome:

(show top 50) (show all 486)
# Title Authors PMID Year
1
Catastrophic antiphospholipid syndrome: is life-long anticoagulation therapy required? 61
32107665 2020
2
Aortitis in the setting of catastrophic antiphospholipid syndrome in a patient with systemic lupus erythematosus. 61
32517572 2020
3
Sudden Cardiac Arrest as the First Manifestation in a Patient with Catastrophic Antiphospholipid Syndrome. 61
32161219 2020
4
Viral infections and their relationship with catastrophic antiphospholipid syndrome: a possible pathogenic mechanism of severe COVID-19 thrombotic complications. 61
32506640 2020
5
Catastrophic antiphospholipid syndrome following the introduction of rivaroxaban. 61
32223511 2020
6
Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature. 61
32252584 2020
7
Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19. 61
32463794 2020
8
Catastrophic Antiphospholipid Syndrome as the Initial Presentation of Waldenstrom Macroglobulinemia. 61
32532610 2020
9
Insights into the pathogenesis of catastrophic antiphospholipid syndrome. A case report of relapsing catastrophic antiphospholipid syndrome and review of the literature on ischemic colitis. 61
31853731 2020
10
Retiform purpura: Workup and therapeutic considerations in select conditions. 61
31479690 2020
11
["STILL IS NOT ENOUGH" - WHAT IS THE DIFFERENTIAL DIAGNOSIS AND THE WORKUP WHEN THE FERRITIN LEVEL IS EXTREMELY HIGH?] 61
32186785 2020
12
A Rare Case of Catastrophic Antiphospholipid Antibody Syndrome: A Case Report and Review of Traditional Cardiovascular Risk Factors Implicated in Disease Occurrence. 61
32274279 2020
13
Catastrophic antiphospholipid syndrome - a case report of a highly fatal disease. 61
32409401 2020
14
Treatment of Vascular Thrombosis in Antiphospholipid Syndrome: An Update. 61
31994163 2020
15
Catastrophic Antiphospholipid Syndrome-Associated Nephropathy in a Systemic Lupus Erythematosus Patient Without Lupus Nephritis. 61
31609535 2020
16
A "Catastrophic" Heparin-Induced Thrombocytopenia. 61
32328108 2020
17
Massive Right Ventricular Thrombus Secondary to Catastrophic Antiphospholipid Syndrome. 61
31985720 2020
18
More Than Skin Deep: A Case of Catastrophic Antiphospholipid Syndrome. 61
31677977 2019
19
MitraClip Detachment and Recapture in a Patient With Catastrophic Antiphospholipid Syndrome. 61
31563685 2019
20
Simultaneous Left and Right Ventricular Thrombi Caused by Catastrophic Antiphospholipid Syndrome. 61
31356115 2019
21
An in vitro model to mimic the thrombotic occlusion of small vessels in catastrophic antiphospholipid syndrome (CAPS). 61
31701800 2019
22
Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome. 61
31808834 2019
23
Plasma exchange in catastrophic antiphospholipid syndrome. 61
31694791 2019
24
Catastrophic Antiphospholipid Syndrome Presenting with Genitourinary Manifestations. 61
31816208 2019
25
Dabigatran for catastrophic antiphospholipid syndrome. 61
31464688 2019
26
Systemic lupus and catastrophic antiphospholipid syndrome manifesting as cardiogenic shock. 61
31451079 2019
27
Thrombotic Storm With Budd-Chiari Syndrome in a Pediatric Patient With Ulcerative Colitis. 61
31832449 2019
28
CAPS criteria fail to identify most severely-ill thrombotic antiphospholipid syndrome patients requiring intensive care unit admission. 61
31253464 2019
29
A catastrophic antiphospholipid syndrome complicated with heparin-induced thrombocytopaenia, successfully managed with double filtration plasmapheresis, steroids and a direct thrombin inhibitor. 61
31527216 2019
30
Successful treatment of catastrophic antiphospholipid syndrome with therapeutic plasma exchange: a case report. 61
31537477 2019
31
Catastrophic antiphospholipid syndrome in pregnancy: a life-threatening condition. 61
31527209 2019
32
Catastrophic Antiphospholipid Syndrome as a Cause of Severe Gastrointestinal Bleeding. 61
30904512 2019
33
Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature. 61
31214910 2019
34
Mortality in patients with systemic lupus erythematosus in Colombia: a case series. 61
30989407 2019
35
Catastrophic antiphospholipid syndrome as a complication of systemic sclerosis. 61
31309781 2019
36
Revisiting the role of therapeutic plasma exchange in the management of catastrophic antiphospholipid syndrome. 61
30720923 2019
37
Catastrophic antiphospholipid syndrome and pregnancy. Clinical report. 61
29284338 2019
38
A case-report of successful use of thromboelastography to manage anticoagulation therapy in a patient with concomitant catastrophic antiphospholipid syndrome and heparin-induced thrombocytopenia. 61
31090599 2019
39
Catastrophic Antiphospholid Syndrome - An Unusual Case Report. 61
31435147 2019
40
A Case of Probable Catastrophic Antiphospholipid Syndrome Treated With Rituximab and Without Anticoagulation. 61
31124923 2019
41
Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab. 61
30844561 2019
42
Strategies for eliciting and synthesizing evidence for guidelines in rare diseases. 61
30922227 2019
43
Rare case of catastrophic antiphospholipid syndrome with spontaneous intracranial haemorrhage. 61
30898956 2019
44
High risk of adverse pregnancy outcomes in women with a persistent lupus anticoagulant. 61
30837214 2019
45
Catastrophic Antiphospholipid Syndrome Presenting as Congestive Heart Failure in a Patient with Thrombotic Microangiopathy. 61
30833839 2019
46
Tumid lupus erythematosus-like pseudovasculitic lesions in catastrophic antiphospholipid syndrome. 61
30733989 2019
47
Alveolar Hemorrhage, a Rare and Life-Threatening Complication of Catastrophic Antiphospholipid Syndrome. 61
31815030 2019
48
Intracardiac thrombus in a patient with catastrophic antiphospholipid syndrome: an autopsy case report and review of the literature. 61
31496715 2019
49
Catastrophic antiphospholipid syndrome causing ST-segment elevation myocardial infarction with non-obstructive coronary arteries. 61
30635301 2019
50
A probable case of catastrophic antiphospholipid syndrome: Should high-dose steroids be given in the setting of polymicrobial sepsis? 61
30967955 2019

Variations for Catastrophic Antiphospholipid Syndrome

Expression for Catastrophic Antiphospholipid Syndrome

Search GEO for disease gene expression data for Catastrophic Antiphospholipid Syndrome.

Pathways for Catastrophic Antiphospholipid Syndrome

GO Terms for Catastrophic Antiphospholipid Syndrome

Cellular components related to Catastrophic Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 SERPINE1 PROC F5 F3 CFH CD40LG
2 cell surface GO:0009986 9.46 F3 CD40LG APOH ADAMTS13
3 extracellular space GO:0005615 9.23 SERPINE1 PROC F5 F3 CFH CD40LG

Biological processes related to Catastrophic Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet degranulation GO:0002576 9.54 SERPINE1 F5 APOH
2 blood coagulation GO:0007596 9.46 PROC F5 F3 ADAMTS13
3 positive regulation of blood coagulation GO:0030194 9.32 SERPINE1 APOH
4 negative regulation of fibrinolysis GO:0051918 9.26 SERPINE1 APOH
5 negative regulation of blood coagulation GO:0030195 9.13 SERPINE1 PROC APOH
6 hemostasis GO:0007599 8.92 PROC F5 F3 ADAMTS13

Sources for Catastrophic Antiphospholipid Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....